NB
HRTX icon

Nicolet Bankshares’s Heron Therapeutics HRTX Stock Holding History

Nicolet Bankshares’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9K Buy
+16,000
New +$18.5K ﹤0.01% 562

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Nicolet Bankshares's HRTX Position: Q1 2026 in Review

Nicolet Bankshares opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 16,000 shares worth $12.9K. The stake represents ﹤0.01% of the portfolio and ranks #562 among its holdings.

167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Nicolet Bankshares held 16,000 shares of Heron Therapeutics worth $12.9K as of Q1 2026.
  • Heron Therapeutics was a new Nicolet Bankshares position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Nicolet Bankshares's portfolio in Q1 2026, its #562 holding.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Nicolet Bankshares's 13F filing for Q1 2026, filed 14 May 2026.